DALLAS & BOSTON–(BUSINESS WIRE)–$CE–Celanese Presents Innovations in EVA Polymers at Targeting Ocular Disorders Conference
Category: Business
National Vision Inc. Announces Nine New Store Openings in August
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Inc., one of the nation’s largest optical retailers providing quality, affordable eye care and eyewear, today announced the opening of nine new store locations in August 2016. National Vision has opened 67 new stores across the U.S. to date in 2016. “We are pleased to expand our national footprint with the opening of these nine new locations as we continue to execute on our growth strategy,” said Bruce Steffey, President and Chief Operating Officer
RightEye Developing Eye-Tracking Tests to Help Doctors Identify Autism and Parkinson’s Disease
WASHINGTON–(BUSINESS WIRE)–#Parkinsons–RightEye LLC announces acquisition of new tests to enable early identification of autism in toddlers and Parkinson’s disease in patients of all ages.
Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today reported the successful 90-day primary efficacy results of its 12-month Phase 3 “Mercury 1” clinical trial for its fixed-dose combination product candidate, RoclatanTM. The study achieved its primary efficacy endpoint demonstra
McKesson a Finalist for PM360 Trailblazer Awards 2016
SCOTTSDALE, Ariz.–(BUSINESS WIRE)–McKesson has been named a 2016 Trailblazer Initiative finalist in the Persistence/Adherence Program Category by PM360.
Phase III Efficacy Results of Investigational Medicine OCREVUS™ (Ocrelizumab) Reinforced by Exploratory Analyses in Two Forms of Multiple Sclerosis
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche group (SIX: RO, ROG; OTCQX: RHHBY), today announced new analyses from the three OCREVUS™ (ocrelizumab) Phase III studies in relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) will be presented during the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), from September 14-17 in London, England. OCREVUS increased disease control in pati
India CR39 Eyeglasses Market Forecasts to 2021 – High Prevalence of Impaired Vision and Increasing Awareness to Fuel Growth Featuring GKB Ophthalmics, Techtran Polylenses & Zeiss – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “India CR39 Eyeglasses Market Forecasts to 2021 – High Prevalence of Impaired Vision and Increasing Awareness to Fuel Growth” report to their offering. The research report …
NovaBay Pharmaceuticals’ Neutrox® Product Line Receives CE Mark and ISO Certification for the European Union
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® lid and lash hygiene in the domestic eye care market, announces that its Neutrox® product line has received the CE mark, clearing the way for this product to be sold in European Union and certain other countries, and ISO 13485 certification, satisfying a critical step in European approval process. “It’s gratifying to report that our N
Pixium Vision recibe la aprobación de la Agencia Española del Medicamento y Productos Sanitarios para realizar un ensayo clínico con el sistema de visión biónica IRIS®II equipado con 150 electrodos
PARIS–(BUSINESS WIRE)–Pixium Vision (FR0011950641 – PIX), una empresa que desarrolla innovadores sistemas de visión biónica para dotar a las personas ciegas de mayor independencia, anunció hoy haber recibido la autorización de la Agencia Española del Medicamento y Productos Sanitarios para realizar un ensayo clínico con el sistema de visión biónica IRIS®II para pacientes que perdieron la visión debido a la retinosis pigmentaria (RP). El sistema IRIS®II incluye una cámara inspirada en el ojo h
Two Studies Demonstrate Promising Results of PiXL™ Procedure (Photorefractive Intrastromal Corneal Collagen Cross-Linking) for Non-Invasive Treatment of Low Myopia
COPENHAGEN, Denmark–(BUSINESS WIRE)–PiXL is a promising non-invasive treatment for vision improvement for low myopia, according to the results of two studies announced today at ESCRS.
Resumen: Novaliq constituye su consejo consultivo científico con prestigiosos expertos internacionales
HEIDELBERG, Alemania–(BUSINESS WIRE)–Novaliq GmbH, una empresa farmacéutica con una plataforma revolucionaria de administración de medicamentos par transformar los fármacos poco solubles en terapias efectivas para oftalmología, ha anunciado la incorporación de varios prestigiosos expertos a su recién constituido consejo consultivo científico (SAB en sus siglas en inglés). El recién constituido SAB asesorará de forma estratégica y respaldará a Novaliq en el desarrollo y salida al mercado de in
Samenvatting: Novaliq benoemt vermaarde experts tot leden wetenschappelijke adviesraad
HEIDELBERG, Duitsland–(BUSINESS WIRE)–Novaliq GmbH heeft vandaag de benoeming van enkele vermaarde experts tot de nieuwe wetenschappelijke adviesraad aangekondigd. De onlangs opgerichte raad adviseert en steunt Novaliq, dat zich bezighoudt met de ontwikkeling en vermarkting van innovatieve therapieën voor uiteenlopende oogheelkundige aandoeningen, zoals het droge-ogensyndroom en glaucoom. Novaliq is een farmaceutisch bedrijf met een ontwrichtend platform voor medicijntoediening, dat moeilijk
Europe Glaucoma Market and Competitive Landscape Highlights 2010-2016 & Forecasts to 2020 – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Europe Glaucoma Market and Competitive Landscape Highlights – 2016” drug pipelines to their offering. Europe Glaucoma Market and Competitive Landscape Highlights – 2016 pr…
Quantros, Inc. Expands Business Coalition Access to CareChex® Data Ratings of Medical Care, Signs Contract with Colorado Business Group on Health
MILPITAS, Calif. & GREENVILLE, S.C.–(BUSINESS WIRE)–Quantros, Inc. Expands Business Coalition Access to CareChex® Data Ratings of Medical Care, Signs Contract with Colorado Business Group on Health
Presbia to Participate in the Rodman & Renshaw 18th Annual Healthcare Conference
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration that has developed the Presbia Flexivue Microlens™, a propriety optical lens implant for treating the age-related loss of near-vision, announced that Jarett Fenton, CFO of Presbia, is scheduled to present at the Rodman & Renshaw 18th Annual Healthcare Conference being held September 11th through 13th at the Lotte New York Palace Hotel in New York City. Mr. Fenton will be a
Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for Rhopressa™ (netarsudil ophthalmic solution) 0.02%
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases…
New Sensor Could Help Fight Deadly Bacterial Infections
WASHINGTON–(BUSINESS WIRE)–#bacteria–Scientists have built a new sensor that can detect the potentially deadly E.coli bacteria in 15-20 minutes, much faster than traditional lab tests.
SalutarisMDが欧州眼科未来フォーラムで滲出型AMD治療の新世代医療機器を発表へ
デンマーク・コペンハーゲン–(BUSINESS WIRE)–（ビジネスワイヤ） — サルタリス・メディカル・デバイシズ・インク(SalutarisMD®)は、9月8日に開催される欧州眼科未来フォーラムにおける当社のプレゼンテーションで、当社が新世代の商用対応の上強膜小線源アプリケーターシステムを紹介すると発表しました。最高経営責任者（CEO）のローレンス・マーステラー医師が、滲出型AMD病変での線量測定を改善し、網膜外科医にとっての使いやすさを向上させるよう、新たなSalutarisMDシステム（SMD-DA™）をデザインしたことについて説明します。当社は出展社ブースでも本システムを展示します。ISO認証の監査とCE申請が進行中で、当社は商用製品について年末までにISO 13485認証とCEマークを取得できると見込んでいます。 当社は最近、新たな機能強化デバイスによる次期臨床試験の承認を米国の規制当局から取得しました。当社は第1世代の臨床デバイスによる先の試験を成功裏に完了しました。先の試験は統計的有意性の推定を意図したものではなかったものの、個々の被験者の結果を追跡しました。
SalutarisMD to Introduce its New Generation Medical Device for wet AMD Therapy at Ophthalmology Futures European Forum
COPENHAGEN, Denmark–(BUSINESS WIRE)–Today, Salutaris Medical Devices, Inc. (SalutarisMD®) announced that during its upcoming presentation at the Ophthalmology Futures European Forum on September 8, the Company will introduce its new generation, commercial ready, episcleral brachytherapy applicator system. The presentation by Dr. Laurence Marsteller, CEO, will discuss how the new SalutarisMD system (SMD-DA™) is designed to deliver improved dosimetry to wet AMD lesions and improved ease of use
SalutarisMD präsentiert sein Medizingerät der neuen Generation zur Therapie der feuchten AMD auf dem Europäischen Ophthalmology Futures Forum
Kopenhagen, Dänemark–(BUSINESS WIRE)–Heute gab Salutaris Medical Devices, Inc. (SalutarisMD®) bekannt, dass das Unternehmen auf dem bevorstehenden Ophthalmology Futures European Forum am 8. September sein für den kommerziellen Einsatz bereites episklerales Brachytherapie-Applikator-System der neuen Generation vorstellen wird. Im Rahmen einer Präsentation wird Dr. Laurence Marsteller, CEO, erörtern, wie das neue SalutarisMD-System (SMD-DA™) eine verbesserte Dosimetrie bei Läsionen einer feucht